What are the reactions after discontinuing the use of Euthyrox?

If a patient with hypothyroidism stops taking euthyrox at the end of the treatment period, there are generally no adverse reactions. However, if the patient stops taking the medication during the treatment period, hypothyroid discomfort symptoms may occur, including reduced appetite, lethargy, fatigue and sleepiness, low mood, and slowed response. If the patient exceeds their tolerable dose or takes too much euthyrox, especially due to a rapid increase in dosage at the beginning of treatment, the following clinical symptoms of thyrotoxicosis may occur, including tachycardia, palpitations, arrhythmias, angina, headaches, muscle weakness and spasms, flushing, fever, vomiting, menstrual disorders, pseudotumor cerebri, tremor, restlessness, insomnia, excessive sweating, weight loss, and diarrhea. In these cases, the patient's daily dosage should be reduced or the medication should be stopped for a few days. Once the above symptoms disappear, the patient should carefully resume medication. Some hypersensitive patients may experience allergic reactions. Before starting thyroid hormone treatment or undergoing thyroid suppression testing, patients should exclude or treat the following diseases: coronary artery insufficiency, angina, arteriosclerosis, hypertension, pituitary insufficiency, adrenal insufficiency, and autonomous hyperfunctioning thyroid adenoma. When initiating levothyroxine treatment in patients with a risk of psychiatric disorders, it is recommended to start with a low dose of levothyroxine and slowly increase the dosage at the beginning of treatment. Monitoring of the patient is recommended. If signs of psychiatric disorders appear, consideration should be given to adjusting the dosage of levothyroxine. Patients with coronary artery insufficiency, cardiac dysfunction, or tachycardia arrhythmias must be careful to avoid even mild symptoms of thyrotoxicosis caused by levothyroxine. Therefore, regular monitoring of thyroid hormone levels in these patients is recommended. For secondary hypothyroidism, the cause must be determined before using this product for replacement treatment, and glucocorticoid supplementation may be necessary if indicated.